Recruiting

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

J1O-MC-JZHD - ClinicalTrials.gov - NCT04106219

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
How long will I be in the trial?
Your participation in this trial could last up to 67 months, depending on your cancer type and how you and your tumor responds.
Email
Recruiting

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

J1O-MC-JZHD - ClinicalTrials.gov - NCT04106219

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
How long will I be in the trial?
Your participation in this trial could last up to 67 months, depending on your cancer type and how you and your tumor responds.
Email

Key Requirements

Age :

2-21

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

2-21

Sex

All

Participants must

Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue

Participants must be able to swallow capsules

Participants must NOT

Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant

Participants must not have untreated tumor that has spread to the brain or spinal cord

Participants must not have a serious active disease other than neuroblastoma

Participants must not have a condition affecting absorption

Participants must not have had prior aurora kinase inhibitor exposure

Participants must not have a known allergy to the study treatment

Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C

Trial Summary

Conditions the trial is for

Neuroblastoma, Pediatric Solid Tumors

What the trial is testing?

LY3295668 Erbumine, Topotecan, Cyclophosphamide

Could I receive a Placebo?

no

Enrollment Goal

71

Trial Dates

June 2020 - April 2025

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

2-21

Sex

All

Participants must

Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue

Participants must be able to swallow capsules

Participants must NOT

Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant

Participants must not have untreated tumor that has spread to the brain or spinal cord

Participants must not have a serious active disease other than neuroblastoma

Participants must not have a condition affecting absorption

Participants must not have had prior aurora kinase inhibitor exposure

Participants must not have a known allergy to the study treatment

Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C

Trial Summary

Conditions the trial is for

Neuroblastoma, Pediatric Solid Tumors

What the trial is testing?

LY3295668 Erbumine, Topotecan, Cyclophosphamide

Could I receive a Placebo?

no

Enrollment Goal

71

Trial Dates

June 2020 - April 2025

Trial Phase

1

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?